At Carmot, we aim to discover, develop and bring disease-modifying therapies to people living with metabolic diseases, including obesity and diabetes.
Modulating the core energy homeostatic pathways is critical to addressing this burden. We leverage technology and discovery expertise to develop novel peptide and small molecule therapeutics that target these pathways.